Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [349]
News [2059]
Articles [63]
Editorials [3]
Conferences [71]
elearning [14]
Adding bevacizumab to standard first-line chemoradiation for glioblastoma gives...
Prof Mark Gilbert - University of Texas MD Anderson Cancer Center, Houston, USA
Adding bevacizumab to standard first-line chemoradiation for glioblastoma gives no survival benefit ( Prof Mark Gilbert - University of Texas MD Anderson Cancer Center, Houston, USA )
6 Jun 2013
Science behind phase I clinical trials: targeting tumour cell development...
Dr Gary K. Schwartz - Memorial Sloan-Kettering Cancer Center, New York, USA
Science behind phase I clinical trials: targeting tumour cell development pathways ( Dr Gary K. Schwartz - Memorial Sloan-Kettering Cancer Center, New York, USA )
6 Jun 2013
No survival benefit to adding bevacizumab to standard first-line chemoradiation...
Dr Mark R. Gilbert - University of Texas MD Anderson Cancer Center, Houston, USA
No survival benefit to adding bevacizumab to standard first-line chemoradiation for glioblastoma ( Dr Mark R. Gilbert - University of Texas MD Anderson Cancer Center, Houston, USA )
2 Jun 2013
Improving outcomes of childhood neuroblastoma
Dr Garrett Brodeur - Cancer Center at The Children’s Hospital of Philadelphia...
Improving outcomes of childhood neuroblastoma ( Dr Garrett Brodeur - Cancer Center at The Children’s Hospital of Philadelphia, USA )
1 Jun 2013
Profiles of malignant GCTs and potential biomarkers for CNS germ cell tumours
Dr Matthew Murray - Cambridge Cancer Centre, UK
Profiles of malignant GCTs and potential biomarkers for CNS germ cell tumours ( Dr Matthew Murray - Cambridge Cancer Centre, UK )
29 May 2013
Epidemiology of central nervous system germ cell tumours
Dr Eric Bouffet - The Hospital for Sick Children, Ontario, Canada
Epidemiology of central nervous system germ cell tumours ( Dr Eric Bouffet - The Hospital for Sick Children, Ontario, Canada )
29 May 2013
Possible consequences and potential for improvement for time of diagnosis for...
Dr Juliet Hale - Newcastle University, UK
Possible consequences and potential for improvement for time of diagnosis for intracranial germ cell tumours ( Dr Juliet Hale - Newcastle University, UK )
29 May 2013
Treatment of primary central nervous system germinoma with chemotherapy
Dr Jonathan Finlay - Children's Hospital Los Angeles, USA
Treatment of primary central nervous system germinoma with chemotherapy ( Dr Jonathan Finlay - Children's Hospital Los Angeles, USA )
29 May 2013
Overview of germ cell tumour research in North America
Dr Stewart Goldman - Children's Memorial Hospital, Chicago, Illinois, USA
Overview of germ cell tumour research in North America ( Dr Stewart Goldman - Children's Memorial Hospital, Chicago, Illinois, USA )
29 May 2013
miR 371-373 and miR 302 cluster expression in body fluids as potential...
Dr Matthew Murray - Cambridge Cancer Centre, UK
miR 371-373 and miR 302 cluster expression in body fluids as potential biomarkers of malignant germ cell tumours ( Dr Matthew Murray - Cambridge Cancer Centre, UK )
29 May 2013
Global microRNA profiles in extracranial and intracranial malignant germ cell...
Dr Matthew Murray - Cambridge Cancer Centre, UK
Global microRNA profiles in extracranial and intracranial malignant germ cell tumours ( Dr Matthew Murray - Cambridge Cancer Centre, UK )
29 May 2013
Time to diagnosis for intracranial germ cell tumours: Possible consequences and...
Dr Juliet Hale - Newcastle University, UK
Time to diagnosis for intracranial germ cell tumours: Possible consequences and potential for improvement ( Dr Juliet Hale - Newcastle University, UK )
29 May 2013

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation